<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2000
BIOTRANSPLANT INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 000-28324 04-3119555
------------------------------- ------------------------- ----------------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
Building 75, Third Avenue
Charlestown Navy Yard
Charlestown, MA 02129
------------------------------------- -----------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: (617) 241-5200
N/A
--------------------------------------------- ----
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
On December 11, 2000, BioTransplant Incorporated announced its plans to acquire
Eligix, Inc. pursuant to an Agreement and Plan of Merger entered into on
December 8, 2000. See the press release attached hereto as Exhibit 99.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: December 11, 2000 BIOTRANSPLANT INCORPORATED
By: /s/ Richard V. Capasso
----------------------------------
Richard V. Capasso
Vice President, Finance and Treasurer
3
<PAGE>
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
Exhibit 99 Press Release dated December 11, 2000
4
